Medical Disclaimer: This content is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any health-related decisions. If you are experiencing a medical emergency, call your local emergency services immediately.
What This Page Explains
Urolithin A and fisetin are two of the most studied longevity compounds, but they target fundamentally different hallmarks of aging. Understanding their differences is essential for choosing the right approach — or, more accurately, understanding why they are best used together. Urolithin A activates mitophagy (selective recycling of damaged mitochondria). Fisetin acts as a senolytic (selective elimination of senescent "zombie" cells). These are complementary mechanisms — urolithin A improves mitochondrial quality while fisetin clears the inflammatory senescent cells that drive tissue aging. Together, they address two of the most important hallmarks of aging.
The 5-Ingredient Formula That Targets All 12 Hallmarks of Aging
See exactly how each ingredient addresses the cellular mechanisms you just read about — backed by the same research cited on this page.
Detailed Evidence
MECHANISM COMPARISON Urolithin A: Activates the PINK1/Parkin mitophagy pathway, selectively removing damaged mitochondria that produce less energy and more oxidative stress. Target: mitochondrial dysfunction (a key hallmark of aging). Fisetin: Inhibits BCL-xL and other anti-apoptotic proteins, selectively eliminating senescent cells that secrete inflammatory SASP factors. Target: cellular senescence (a key hallmark of aging). HUMAN EVIDENCE COMPARISON Urolithin A: Strong human evidence. The 2022 JAMA Network Open RCT showed improved mitochondrial biomarkers (500mg/day), muscle endurance (1,000mg/day), and reduced inflammation (up to 53%). FDA GRAS status (2020). Multiple human trials. Fisetin: Limited human evidence. The 2018 Mayo Clinic senolytic screening was preclinical. Human trials (COVFIS, NCT06133634 vascular trial) are early-stage or ongoing. No published human trial demonstrates senolytic activity in vivo. No FDA GRAS status. DOSING COMPARISON Urolithin A: Daily dosing (500-1,000mg/day) for sustained mitochondrial support. Four months in the JAMA trial. Fisetin: Intermittent senolytic dosing (typically 2 days per month at 20mg/kg). Intermittent dosing reflects the senolytic hypothesis of periodic clearance. SAFETY COMPARISON Urolithin A: FDA GRAS status, no serious adverse events in multiple trials, strong safety profile. Fisetin: Limited human safety data from small trials. Preclinical safety is favourable but human safety data is less established than urolithin A. BIOAVAILABILITY COMPARISON Urolithin A: Reliable absorption with direct supplementation; bypasses gut bacteria bottleneck. Fisetin: Poor oral bioavailability (<10%); BCS Class IV compound requiring enhanced formulations. WHY THEY ARE COMPLEMENTARY Urolithin A reduces the primary fuel source for SASP inflammatory output by removing damaged mitochondria, making it directly complementary to fisetin's senolytic activity. Fisetin clears the senescent cells; urolithin A ensures the remaining cells have healthy mitochondria. Together they address both the "zombie cell" problem and the "damaged mitochondria" problem — two of the most important drivers of cellular aging.
Evidence Hierarchy
Systematic Reviews & Meta-Analyses
Multiple high-quality trials combined
Randomized Controlled Trials (RCTs)
Gold standard for treatment efficacy
Observational Studies
Can show associations, not causation
Case Reports & Expert Opinion
Hypothesis-generating only
Preclinical (Lab/Animal) Studies
Should NOT be extrapolated to humans
The Science on This Page Points to One Conclusion
Your cells need targeted support — not more vitamins, not more caffeine, not more wishful thinking. Real compounds for real cellular mechanisms.
Study Quality Indicators
Higher Quality Indicators
- Large sample size (hundreds to thousands)
- Randomized and blinded design
- Placebo-controlled comparison
- Published in peer-reviewed journals
- Replicated in multiple studies
- Registered trial protocol before starting
Lower Quality Indicators
- Small sample size (under 100)
- No control group or blinding
- Manufacturer-funded with conflicts
- Only animal/cell studies
- Never replicated
- Published in predatory journals
Important Limitations
- • Supplement research often has methodological limitations
- • Results from one study may not generalize to all people
- • Marketing claims often exceed what research supports
- • Absence of evidence is not evidence of absence
- • Individual response to supplements varies widely
Quick Answers
Is urolithin A or fisetin better?
They are complementary, not competitors. Urolithin A activates mitophagy (mitochondrial recycling) while fisetin acts as a senolytic (clearing senescent cells). Together they address two key hallmarks of aging.
Can I take urolithin A and fisetin together?
Yes. They target different aging pathways and are complementary. Urolithin A reduces the SASP fuel source from damaged mitochondria, complementing fisetin's senolytic activity. Consult a healthcare provider for personalised advice.
Which has stronger human evidence?
Urolithin A has stronger human evidence — multiple RCTs including the JAMA Network Open trial with functional outcomes. Fisetin's human evidence is early-stage with no published trial demonstrating in vivo senolytic activity.
Which is safer?
Urolithin A has a stronger documented safety profile — FDA GRAS status and no serious adverse events in multiple trials. Fisetin has limited human safety data from small trials.
Do they target the same thing?
No. Urolithin A targets mitochondrial dysfunction (mitophagy). Fisetin targets cellular senescence (senolytic). These are different hallmarks of aging.
How do their dosing schedules differ?
Urolithin A is daily (500-1,000mg/day) for sustained mitochondrial support. Fisetin is intermittent (typically 2 days/month at 20mg/kg) reflecting the senolytic hypothesis of periodic clearance.
Which has better bioavailability?
Urolithin A has reliable absorption with direct supplementation. Fisetin has poor oral bioavailability (<10%) and is a BCS Class IV compound requiring enhanced formulations.
Is urolithin A FDA approved?
Urolithin A received FDA GRAS status in 2020. Fisetin has not received GRAS status. Neither is FDA-approved to treat disease.
Which is better for energy?
Urolithin A directly improves mitochondrial function (the energy producers), so it is more directly relevant to energy. Fisetin indirectly supports energy by reducing inflammatory burden.
Which is better for inflammation?
Both help. Fisetin clears senescent cells (the source of SASP inflammation). Urolithin A reduced inflammatory markers by up to 53% at 1,000mg/day in the JAMA trial.
Which is better for aging?
Both target key hallmarks of aging. They are best used together — fisetin for senescent cell clearance, urolithin A for mitochondrial quality. Neither alone addresses all aging pathways.
Are they redundant?
No. They target complementary mechanisms. Urolithin A reduces SASP fuel by removing damaged mitochondria; fisetin removes the senescent cells that produce SASP. Together they address both cause and effect.
Which is more affordable?
Prices vary by brand and formulation. Urolithin A tends to be more expensive due to the proprietary production process. Fisetin is generally less expensive but may require enhanced formulations for absorption.
Should I start with one or both?
This depends on your goals and budget. Consult a healthcare provider. Many longevity protocols use both together, but each can be used individually for its specific mechanism.
Which is better studied?
Urolithin A is better studied in humans with multiple RCTs and functional outcomes. Fisetin is better studied preclinically with the landmark 2018 senolytic screening but limited human evidence.
Key Research Facts
Urolithin A activates mitophagy (mitochondrial recycling) while fisetin acts as a senolytic (senescent cell clearance) — they target different hallmarks of aging.
Strong EvidenceJAMA Network Open + EBioMedicine — combined mechanism review
Urolithin A has stronger human evidence: multiple RCTs including JAMA Network Open with functional outcomes. Fisetin's human evidence is early-stage.
Strong EvidenceClinical trial literature review
Urolithin A received FDA GRAS status (2020); fisetin has not. Neither is FDA-approved to treat disease.
Strong EvidenceFDA GRAS Notice — Amazentis, 2020
Urolithin A is dosed daily (500-1,000mg/day); fisetin is dosed intermittently (typically 2 days/month at 20mg/kg) reflecting their different mechanisms.
Strong EvidenceClinical trial protocols — dosing comparison
Urolithin A has reliable absorption; fisetin has poor oral bioavailability (<10%) as a BCS Class IV compound.
Strong EvidenceGrynkiewicz & Demchuk, Frontiers in Chemistry — doi:10.3389/fchem.2019.00159
Urolithin A reduces the SASP fuel source from damaged mitochondria, making it directly complementary to fisetin's senolytic activity.
Moderate EvidenceMechanistic analysis — mitophagy and SASP interaction
The JAMA trial showed 1,000mg/day urolithin A reduced inflammatory markers by up to 53% — fisetin's human anti-inflammatory data is limited.
Strong EvidenceJAMA Network Open — Singh et al. 2022
Both compounds are best used together in longevity protocols — they address two of the most important hallmarks of aging.
Moderate EvidenceLongevity stack research — combination protocols
Urolithin A is more directly relevant to energy (mitochondrial function); fisetin indirectly supports energy by reducing inflammatory burden.
Moderate EvidenceMechanism comparison — energy pathways
No published study has directly compared urolithin A and fisetin head-to-head in a single trial — comparison is based on separate trial data and mechanism analysis.
Strong EvidenceClinical literature review — comparative analysis
Citations & External Resources
JAMA Network Open — Singh et al. 2022 (Urolithin A RCT)
EBioMedicine — Yousefzadeh et al. 2018 (Fisetin Senolytic)
FDA GRAS Notice — Urolithin A (Amazentis, 2020)
Frontiers in Chemistry — Fisetin Bioavailability
NCT06133634 — Fisetin Vascular Function Trial
Nature Metabolism — Urolithin Metabotypes Study (2021)
If You're Over 45 And Tired of Feeling Tired, Read This
Most people blame aging for their energy crash. The real culprit? Dysfunctional mitochondria. There's a science-backed solution.
Related Reading
Urolithin A: The Complete Evidence-Based Guide
Fisetin: The Complete Evidence-Based Guide
Urolithin A: How It Works (Mitophagy Mechanisms)
References (3)
Written by
ReCellence™ Editorial Team
Health Content Specialists
Medically reviewed by
Medical Review Board
MD, PhD
Last updated: March 8, 2026
Last medical review: March 8, 2026